Association of baseline serum sodium with long-term outcomes in newly diagnosed coronary heart disease patients without heart failure: a prospective cohort study

• Published in: Scientific reports Vol. 14; no. 1; pp. 18154 - 14
• Main Authors: Cao, Zelong, Zhu, Wenqing, Shen, Chaonan, Gao, Bo, Jin, Naying, Li, Fang, Zhang, Bin, Liu, Gang, Zheng, Liang, Zheng, Mingqi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 06.08.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/163; 692/308/409; 692/4019; 692/499; Aged; Cardiovascular disease; Cardiovascular diseases; Cardiovascular risk; Cohort analysis; Congestive heart failure; Coronary artery disease; Coronary Disease - blood; Coronary Disease - diagnosis; Coronary heart disease; Female; Follow-Up Studies; Health hazards; Health risks; Heart diseases; Heart failure; Heart Failure - blood; Humanities and Social Sciences; Humans; Major adverse cardiovascular events; Male; Middle Aged; multidisciplinary; Myocardial infarction; Prediction models; Prognosis; Prognostic biomarkers; Proportional Hazards Models; Prospective Studies; Risk Factors; Science; Science (multidisciplinary); Serum sodium; Sodium; Sodium - blood; Prognostic biomarkers; Major adverse cardiovascular events; Coronary heart disease; Cardiovascular risk; Serum sodium
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-69342-2

Sodium is crucial for maintaining cardiovascular health, especially in relation to heart failure. The impact of baseline serum sodium concentrations on the outcomes of newly diagnosed coronary heart disease (CHD) without heart failure remains unclear. This prospective cohort study included 681 patients who were newly diagnosed with CHD. Cox proportional hazards models and restricted cubic spline (RCS) analysis were used to assess the relationship between serum sodium concentrations and major adverse cardiovascular events. The improvement in traditional prediction models by the addition of serum sodium concentrations was assessed using changes in the C-statistic, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). During a median follow-up of 51.04 months (IQR: 40.88–53.80 months), 131 events were recorded. Multivariate Cox proportional hazards models showed that the L2 group (136–138.9 mmol/L) had the highest MACE risk. Compared to L2, the hazard ratios (HRs) and 95% confidence intervals (CIs) for the L1 (130–135.9 mmol/L), L3 (139–140.9 mmol/L), L4 (141–142.9 mmol/L), and L5 (143–147.0 mmol/L) groups were 0.31 (0.14–0.70, P  = 0.005), 0.48 (030–0.78, P  = 0.003), 0.56 (0.34–0.92, P  = 0.022), and 0.37 (0.22–0.64, P  < 0.001), respectively. Including serum sodium concentrations in the prediction model significantly improved the C-statistic from 0.647 to 0.679 ( P  = 0.022), with an NRI of 0.338 ( P  < 0.001) and an IDI of 0.026 ( P  < 0.001). RCS analysis showed a nonlinear relationship: within the 130–138 mmol/L sodium range, MACE risk gradually increased with higher sodium levels (HR 1.39, 95% CI 1.09–1.76, P  = 0.008); whereas within the 138–147 mmol/L range, the risk gradually decreased (HR 0.88, 95% CI 0.80–0.98, P  = 0.014). Baseline serum sodium concentrations are significantly associated with long-term cardiovascular risk in newly diagnosed CHD patients, showing an inverted U-shaped relationship, whereas low serum sodium may be specifically linked to higher risks of death and nonfatal myocardial infarction. Further research is needed to explore the impact of long-term changes in serum sodium concentrations on disease prognosis.